Cancer Genetics Inc (CGIX) CEO Acquires $23,000.00 in Stock

Cancer Genetics Inc (NASDAQ:CGIX) CEO John A. Roberts acquired 100,000 shares of Cancer Genetics stock in a transaction dated Monday, January 14th. The shares were acquired at an average cost of $0.23 per share, with a total value of $23,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 112,200 shares in the company, valued at approximately $25,806. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of CGIX stock opened at $0.31 on Friday. Cancer Genetics Inc has a 12-month low of $0.20 and a 12-month high of $2.20. The stock has a market cap of $7.21 million, a P/E ratio of -0.39 and a beta of 0.96. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.05.

Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings results on Monday, November 19th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.07). Cancer Genetics had a negative net margin of 87.08% and a negative return on equity of 121.10%. The firm had revenue of $5.94 million for the quarter, compared to the consensus estimate of $8.09 million.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc lifted its holdings in Cancer Genetics by 119.8% during the 3rd quarter. Vanguard Group Inc now owns 532,426 shares of the medical research company’s stock valued at $554,000 after purchasing an additional 290,146 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Cancer Genetics by 119.8% during the 3rd quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock valued at $554,000 after purchasing an additional 290,146 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Cancer Genetics by 15.0% during the 3rd quarter. Renaissance Technologies LLC now owns 675,200 shares of the medical research company’s stock valued at $702,000 after purchasing an additional 87,900 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its holdings in Cancer Genetics by 28.1% during the 3rd quarter. Perkins Capital Management Inc. now owns 1,287,250 shares of the medical research company’s stock valued at $1,339,000 after purchasing an additional 282,700 shares during the last quarter. 14.76% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently commented on CGIX. ValuEngine raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Maxim Group reaffirmed a “hold” rating on shares of Cancer Genetics in a report on Tuesday, November 20th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $4.50.

TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2019/01/18/cancer-genetics-inc-cgix-ceo-acquires-23000-00-in-stock.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Read More: Why do companies issue stock splits?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit